NEW YORK (GenomeWeb News) – GNS Healthcare and the CHDI Foundation jointly announced today that they will collaborate on the development of a data-driven computer model of Huntington's disease intended to drive personalized medicine research.
The alliance will make use of GNS' Reverse Engineering and Forward Simulation platform to develop network models from genomic, expression, and cell signaling data. The partners expect that results from millions of in silico simulations of the REFS models will provide insight into the mechanisms of Huntington's disease and lead to more effective treatments.
"This collaboration with CHDI is representative of our focus on using big data analytics to reveal new insights into a disease and provide tools for scientists that will help transform the tremendous amount of information coming from new technologies such as next-generation sequencing into predictive computer models of disease progression and drug response," GNS Executive VP and Co-founder Iya Khalil.
Once the REFS models are completed they will be transferred to CHDI and its affiliated researchers.